Azitra (AZTR) Q4 2024 earnings summary

Executive summary

• Initiated Phase 1b clinical trial for ATR-12 in Netherton syndrome; topline data expected by year-end 2025.

• Received FDA clearance and Fast Track designation for ATR-04 targeting EGFRi-associated dermal toxicity; Phase 1/2 trial to begin in first half of 2025.

• Closed $15 million in public offerings and strengthened IP portfolio with new patents.

Financial highlights

• Service revenue was $0.8 thousand for 2024, down from $0.7 million in 2023.

• R&D expenses rose to $4.7 million from $3.6 million year-over-year.

• G&A expenses increased to $6.3 million from $4.5 million year-over-year.

• Net loss narrowed to $9.0 million for 2024, compared to $11.3 million in 2023.

• Cash and cash equivalents were $4.6 million at year-end 2024, excluding $2.2 million raised in early 2025.

Outlook and guidance

• Initial safety data for ATR-12 expected in first half of 2025; topline Phase 1b results by year-end 2025.

• First patient dosing for ATR-04 Phase 1/2 trial anticipated in first half of 2025.

• Multiple value-building milestones expected in 2025, including clinical data releases.